Statin Therapy and New-onset Diabetes: Molecular Mechanisms and Clinical Relevance

Author(s): Maciej Banach, Malgorzata Malodobra-Mazur, Anna Gluba, Niki Katsiki, Jacek Rysz, Agnieszka Dobrzyn

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 27 , 2013

Become EABM
Become Reviewer
Call for Editor


Despite positive effects on the plasma lipid profile and vascular events, statin use is associated with various side effects. Among these, statins might cause a disruption of a number of regulatory pathways including insulin signaling. This may affect insulin sensitivity, pancreatic beta-cell function and adipokine secretion. The statin-associated risk of new-onset diabetes (NOD) appears to be a dose-dependent class effect. It still remains unclear whether statin treatment is associated with increased risk of NOD in the general population or if there are groups of individuals at particular risk. However, according to the available data it seems that cardiovascular (CV) benefits in high-risk individuals strongly favor statin therapy since it outweighs other risks. Whether statins should be used for primary prevention among patients with a relatively low baseline CV risk is still questionable, however the results of primary prevention trials have shown reductions in mortality in this population. Thus, there is a need for randomized, placebo-controlled statin studies with carefully selected groups of patients and NOD as a key end point in order to resolve queries concerning this issue.

Keywords: Insulin resistance, lipids, new-onset diabetes mellitus, statins, therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [4904 - 4912]
Pages: 9
DOI: 10.2174/1381612811319270014
Price: $65

Article Metrics

PDF: 44